EVER PHARMA

STROKE

TBI

DEMENTIA

# Cerebrolysin® as an Adjunct Therapy to Mechanical Thrombectomy

## A 12-Month Follow-up Study

*Staszewski, J., Dębiec, A., Gniadek-Olejniczak, K. et al. Cerebrolysin after Endovascular Thrombectomy in Stroke: 12 Month Functional Outcomes in a Propensity Matched Cohort. Transl. Stroke Res. 17, 28 (2026).*

**First study with 12-month follow-up data for adjunct Cerebrolysin® treatment**

- Significant Improvement of Functional Independence
- Early and Continous Recovery
- Improved Activities of Daily Living
- Lower Need for Institutional Care

Cerebrolysin®

**Reconnecting Neurons.**
**Empowering for Life.**

# Significant Improvement of Functional Independence

## Favorable mRS shift at 12 months in Cerebrolysin-treated patients




- **Significant results** at 12 months
- **Better functional independence** (mRS 0-2) in Cerebrolysin-treated patients
- **74 % of patients** achieved improved functional independece **at 12 months** vs. only 46 % of patients in the control group

# Early and Continuous Recovery

## Increasing functional independence in Cerebrolysin-treated patients over 12 months




- As the baseline characteristics are well matched between the groups, the **higher mRS 0-2 at Day 7** in the **Cerebrolysin group** indicates early recovery
- **Significantly better outcomes** at Day 7 only in the **Cerebrolysin group**
- The **second treatment cycle boosted** the number of independent patients at 12 months

# Improved Activities of Daily Living

## Cerebrolysin-treated patients show only slight dependency at 12 months




- **Baseline characteristics** between Cerebrolysin and Control group are **well matched**
- At 12 months, **Cerebrolysin patients** improved to **Barthel Index (BI) score of 92**, indicating only **slight dependency**
- In contrast, **controls** only reach a **score of 83**, remaining in the **moderate dependency** category, unchanged from days 30 and 90
- Already by day 30, **Cerebrolysin-treated** patients show **greater independence** compared to the control group, enabling **earlier rehabilitation**

# Lower Need for Institutional Care

## Two fold reduction (13 %) of institutional care in the Cerebrolysin group




- At 12 months, **only 6 %** of Cerebrolysin-treated patients **required institutional care**, compared to 19 % in the control group
- Cerebrolysin shows a **clear reduction in care** at 90 days and also after 12 months
- **Cerebrolysin** treatment has longterm effects on **cost reduction** in institutional care facilities (increased cost reduction between 90 days and 12 month)

# Start with Cerebrolysin® as early as possible after moderate-severe AIS

- Significant improvement of functional independence at 90 days continued to 12 months
- Lower need for institutional care, 10 % lower after 90 days and even 13 % lower after 12 months
- Significant improvement in activities of daily living at 1, 3 and 12 months

| Daily dosage | Initiation of treatment | Treatment Duration |
|---|---|---|
| 30 ml | as soon as possible<br>ideally from day 1 | 21 days |


**Titel:** Cerebrolysin after Endovascular Thrombectomy in Stroke: 12 Month Functional Outcomes in a Propensity Matched Cohort. Transl. Stroke Res. 17, 28 (2026).
**Author:** Staszewski et al., 2026
**Journal:** Springer Nature - Translational Stroke Research

**Titel:** Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Transl. Stroke Res. 16, 1931–1946 (2025).
**Author:** Staszewski et al., 2025
**Journal:** Springer Nature - Translational Stroke Research



ABBREVIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 2.0/03.06.2016) EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria, www.everpharma.com, www.cerebrolysin.com


CERE/INT/04/2026/03